A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Chemotherapy in Participants With Non-Hodgkin Lymphomas

Cancer
Non Hodgkin Lymphoma (NHL)
Follicular Lymphoma
B-cell Non-Hodgkin Lymphoma

Results
Download

Study results

LPS NP40126 Final Results October 2025 English (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 Danish (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 French (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 Spanish (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 Canada English (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 USA English (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 German (PDF, 0.9 MB)

LPS NP40126 Final Results October 2025 Australia English (PDF, 0.8 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Chemotherapy in Participants With Non-Hodgkin Lymphomas

Study results

LPS NP40126 Final Results October 2025 English (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 Danish (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 French (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 Spanish (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 Canada English (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 USA English (PDF, 0.8 MB)

LPS NP40126 Final Results October 2025 German (PDF, 0.9 MB)

LPS NP40126 Final Results October 2025 Australia English (PDF, 0.8 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

External Site

Directly contact Roche for questions

Contact the hospital directly

You are about to leave ForPatients

Thank you

Request a call back

Find participating medical centers and current study status in each of them

A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Chemotherapy in Participants With Non-Hodgkin Lymphomas

For the latest version of this information please go to www.forpatients.roche.com